HLA-A*0201-Restricted URLC10-VEGFR1-VEGFR2 Multipeptide Vaccine

A cancer vaccine containing three HLA-A*0201-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. (NCI Thesaurus)

YOU MAY ALSO LIKE

HLA-A*0201-restricted TRP2-gp100-EphA2-HER2 multipeptide Vaccine

A cancer vaccine containing four HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor…

HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001

A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT),…

HLA-A wt Allele

Human HLA-A wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes…

HLA-A Gene

This gene is involved in immune responses and histocompatibility processes.

HLA Typing

A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles.

HLA matching

A process in which blood or tissue samples are tested for human leukocyte antigens (HLAs). HLAs are molecules found on the surface…